Neuware - The Symposium on New Drugs provides a forum for academic investigators, research and development personnel from the pharmaceutical industry and members of the Food and Drug Administration to discuss important clinical research issues. The Ninth Annual symposium on New Drugs addressed the problem of determining the risk versus benefit for use of three important classes of cardiovascular agents: thrombolytic, antiarrhythmic, and hypolipidemic agents. The use of thrombolytic agents has become one of the major advances in clinical intensive cardiologic care in the 1980s. While the lysis of clot(s) obstructing a major coronary artery should reverse or prevent the damage of acute myocardial ischemia and infarction, one must carefully consider the potential risks of such agents in regards to their potential benefits. The time when a thrombolytic agent should be administered to maximize benefit as well as how one defines a dose response relationship using intravenous critical care medicines were discussed as important clinical trial issues. The benefit versus risk data on currently available thrombolytic agents was reviewed and the potential roles for adjunctive agents addressed. Overall strategies regarding post- x thrombolytic care and relationships to sudden cardiac death were also detailed. The panel discussion sections provided a comprehensive view of the current thinking of the various participating groups in this symposium. Sudden cardiac death remains the number one cause of mortality in western industrialized societies. N� de ref. del art�culo 9780792302940

Contactar al vendedor

Denunciar este art�culo

Detalles bibliogr�ficos

T�tulo: Risk/Benefit Analysis for the Use and ...

Editorial: Springer Us Jun 1989

A�o de publicaci�n: 1989

Encuadernaci�n: Buch

Condici�n: Neu

Acerca de

Sinopsis:

The Symposium on New Drugs provides a forum for academic investigators, research and development personnel from the pharmaceutical industry and members of the Food and Drug Administration to discuss important clinical research issues. The Ninth Annual symposium on New Drugs addressed the problem of determining the risk versus benefit for use of three important classes of cardiovascular agents: thrombolytic, antiarrhythmic, and hypolipidemic agents. The use of thrombolytic agents has become one of the major advances in clinical intensive cardiologic care in the 1980s. While the lysis of clot(s) obstructing a major coronary artery should reverse or prevent the damage of acute myocardial ischemia and infarction, one must carefully consider the potential risks of such agents in regards to their potential benefits. The time when a thrombolytic agent should be administered to maximize benefit as well as how one defines a dose response relationship using intravenous critical care medicines were discussed as important clinical trial issues. The benefit versus risk data on currently available thrombolytic agents was reviewed and the potential roles for adjunctive agents addressed. Overall strategies regarding post- x thrombolytic care and relationships to sudden cardiac death were also detailed. The panel discussion sections provided a comprehensive view of the current thinking of the various participating groups in this symposium. Sudden cardiac death remains the number one cause of mortality in western industrialized societies.

Rese�a del editor:

"Sobre este t�tulo" puede pertenecer a otra edici�n de este libro.

Descripci�n de la librer�a

Das Unternehmen AHA-BUCH GmbH: Seit der Gr�ndung von AHA-BUCH im Juli 2005 ist unser Hauptziel, zufriedenen Kunden so schnell und so preisg�nstig wie m�glich ihren B�cherwunsch zu erf�llen. Unsere Firma besch�ftigt 16 Mitarbeiter, die nur ein Ziel kennen: den Kunden und seine W�nsche! Auf �ber 3700 m2 Fl�che haben wir �ber 100.000 B�cher, Modernes Antiquariat und Spiele auf Lager.

Ver la p�gina web de la librer�a

Informaci�n empresarial del vendedor

AHA-BUCH GmbH
Garlebsen 48, Einbeck, 37574, Germany

Condiciones de venta:

T�rminos y Condiciones Generales e Informaci�n del Cliente / Pol�tica de Privacidad

I. T�rminos y Condiciones Generales

� 1 Disposiciones b�sicas

(1)Los siguientes t�rminos y condiciones se aplican a todos los contratos que celebre con nosotros como proveedor (AHA-BUCH GmbH) a trav�s de las plataformas de Internet AbeBooks y/o ZVAB. A menos que se acuerde lo contrario, se objetar� la inclusi�n de cualquiera de sus propios t�rminos y condiciones utilizados por usted.
(2)Un consumidor en el sentid...

M�s informaci�n

Condiciones de env�o:

Enviamos su pedido despu�s de recibirlos
para art�culos disponibles las �ltimas 24 horas,
para art�culos con suministro nocturno a m�s tardar 48 horas.
En caso de que necesitemos pedir un art�culo a nuestro proveedor, nuestro tiempo de env�o depende de la fecha de recepci�n de los art�culos, pero los art�culos se enviar�n el mismo d�a.

Nuestro objetivo es enviar los art�culos pedidos de la manera m�s r�pida, pero tambi�n m�s eficiente y segura a nuestros clientes.

Informaci�n detallada sobre el vendedor

M�todos de pago
aceptados por la librer�a